Gene Therapy for Toddlers, an Oral GLP-1 Milestone, and West Nile's Worst Start in Two Decades

This week's Health & Medicine roundup covers six stories: a historic expansion of CRISPR-based medicine to the youngest patients yet, a CDC warning about the most intense early West Nile season in two decades, two regulatory milestones for rare and chronic diseases, a new oral GLP-1 result published in The Lancet, and a growing foodborne parasite outbreak spreading across 18 American states.

Wednesday, 1 July: FDA Expands CRISPR Gene Therapy to Children as Young as Two

The U.S. Food and Drug Administration approved a supplemental indication for Casgevy (exagamglogene autotemcel) — the world's first CRISPR-based medicine to reach patients — extending its use to children aged two years and older with sickle cell disease (SCD) who experience recurrent vaso-occlusive crises.

Casgevy was originally approved in December 2023 for patients aged 12 and older. The new expansion relied on safety and efficacy data from patients aged 5–11, with the 2-to-4 age cohort covered through regulatory extrapolation based on the therapy's mechanism of action. The one-time treatment works by extracting a patient's own haematopoietic stem cells, editing them with CRISPR/Cas9 to reactivate fetal haemoglobin production, and reinfusing the corrected cells via intravenous infusion. Regulators estimate the label expansion opens access for approximately 5,500 additional children in the United States.

Sickle cell disease disproportionately affects people of sub-Saharan African, Mediterranean, Middle Eastern, and South Asian descent — communities well represented in Cyprus and the broader eastern Mediterranean. The therapy is not yet routinely available in Europe, but the U.S. milestone marks real progress in gene-based cures and is expected to shape regulatory planning at the EMA in coming years.

Thursday, 2 July: West Nile Season at Its Worst Start in 22 Years, CDC Warns

The CDC issued a public health advisory describing the 2026 West Nile virus season as the most intense early-summer outbreak since 2004. As of 30 June, at least 48 confirmed human cases had been reported across 23 states — nearly five times the historical average of about 10 cases by late June. Four deaths had already been recorded, all in Arizona's Maricopa County, which is the epicentre of this year's surge.

More concerning, 38 of the 48 cases are classified as neuroinvasive disease — the severe form in which the virus crosses into the brain or spinal cord to cause encephalitis, meningitis, or acute flaccid myelitis. The CDC's historical reference point is 2004, when West Nile started at a similarly early pace and ended that year with more than 2,500 cases and 100 deaths nationally.

West Nile virus is transmitted by Culex mosquitoes; there is no approved human vaccine and no specific antiviral treatment. Prevention is entirely behavioural: applying DEET- or picaridin-based repellents, wearing long-sleeved clothing at dusk and dawn, eliminating standing water near the home, and keeping windows and doors screened. These precautions are equally relevant in Cyprus and across the Mediterranean, where Culex mosquitoes are active throughout summer and sporadic West Nile cases are reported annually.

Tuesday, 7 July: FDA Approves First Dual-Cytokine Blocker for Kidney Disease

The FDA granted accelerated approval to Trutakna (atacicept-vymj) — developed by Vera Therapeutics — for adults with primary IgA nephropathy (IgAN) at risk of disease progression.

IgA nephropathy is the most common primary kidney disease worldwide. It is caused by abnormal deposits of immunoglobulin A in the kidney's glomerular filtering structures, which trigger inflammation that, over years to decades, can progress to kidney failure. Effective treatment options have historically been limited.

Trutakna is the first approved therapy to simultaneously inhibit both BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand) — two immune proteins that sit early in the pathological cascade of IgAN. In the ORIGIN 3 trial's prespecified interim analysis, the drug reduced proteinuria by 46% from baseline, a statistically significant 42% greater reduction than placebo at 36 weeks. The accelerated approval rests on proteinuria reduction as a surrogate endpoint. Whether Trutakna also slows the long-term decline in kidney function remains to be confirmed by the ongoing blinded portion of ORIGIN 3, which is expected to report in the third quarter of 2026. Trutakna is self-administered once weekly as a subcutaneous injection.

Tuesday, 7 July: Oral GLP-1 Pill Outperforms Oral Semaglutide in Phase 3 Head-to-Head Trial

Eli Lilly published results from ACHIEVE-3 in The Lancet — a 52-week Phase 3 trial directly comparing orforglipron, an oral small-molecule GLP-1 receptor agonist, with oral semaglutide (Rybelsus) in 1,698 adults with type 2 diabetes inadequately controlled on metformin. Orforglipron outperformed oral semaglutide on the primary endpoint of HbA1c reduction and on all key secondary endpoints, including body weight, blood pressure, and waist circumference.

Unlike peptide-based GLP-1 drugs such as semaglutide, orforglipron is a small molecule: it requires no refrigeration and carries no food or water restrictions around dosing — practical features that could substantially improve real-world adherence and reduce manufacturing costs. Tolerability was consistent with the GLP-1 class, with mild-to-moderate gastrointestinal side effects concentrated during dose escalation. A companion Phase 3 trial, ATTAIN-2, published separately in The Lancet, showed orforglipron achieving up to 9.6% body weight reduction at 72 weeks in adults with obesity and type 2 diabetes.

Lilly has indicated that global regulatory submissions for an obesity indication are planned for this year. An oral GLP-1 with no cold-chain requirement and no meal-timing constraints could meaningfully extend access to effective metabolic treatment in community health settings and lower-resource environments.

Tuesday, 7 July: Cyclosporiasis Outbreak Expands to 18 States

The CDC and FDA are jointly investigating a growing outbreak of cyclosporiasis — an intestinal illness caused by the microscopic parasite Cyclospora cayetanensis — that has reached 18 states, with 843 confirmed domestically acquired cases and more than 1,500 additional cases still under investigation.

Cyclospora is not transmitted from person to person; infection follows ingestion of fresh produce or water contaminated with human faecal matter. Implicated foods in past outbreaks have included basil, cilantro, spinach, leafy greens, and fresh berries. Symptoms begin 7–10 days after exposure and include watery or explosive diarrhoea, abdominal cramps, nausea, and prolonged fatigue. Without treatment with trimethoprim-sulfamethoxazole, the illness can last for weeks and relapse.

As of 7 July, no single food source had been identified to explain all outbreak clusters; several separate investigations are running in parallel. Clinicians are advised to consider cyclosporiasis in patients presenting with prolonged diarrhoea following consumption of fresh produce, and to test where possible. The public is advised to wash all fresh fruit and vegetables thoroughly before eating.

Decision Due Friday, 17 July: FDA Reviews Gedatolisib for Advanced Breast Cancer

The FDA has a Prescription Drug User Fee Act (PDUFA) goal date of 17 July 2026 for gedatolisib (Celcuity), a dual PI3K/mTOR inhibitor under review for use in combination with fulvestrant — with or without palbociclib — in adults with hormone receptor-positive, HER2-negative advanced breast cancer carrying a PIK3CA mutation who have progressed on a CDK4/6 inhibitor and an aromatase inhibitor. This setting represents one of the largest unmet needs in breast oncology.

Phase 3 VIKTORIA-1 data, published in the Journal of Clinical Oncology, showed gedatolisib-based regimens reduced the risk of disease progression or death by approximately 50% compared with alpelisib plus fulvestrant. Clinically meaningful differentiation in tolerability was also demonstrated: grade 3 hyperglycaemia occurred in only 2.6% of patients on gedatolisib versus 13.8% on alpelisib — a side effect that has historically limited how widely PI3K inhibitors can be used. Stomatitis was more common with gedatolisib.

If the FDA approves gedatolisib on or around 17 July, it would add a meaningful option in a setting where effective treatment after CDK4/6 inhibitor failure remains scarce.

---

The content in this article is journalistic in nature and does not constitute medical advice. Readers should consult a qualified healthcare professional before making any change to their treatment plan, medications, or health management.